Events on 27 September 2023

CONGRESS 2023 - Effects of direct thrombin inhibitors [dabigatran/argatroban/bivalirudin] on tests of haemostasis

Effects of direct thrombin inhibitors [dabigatran/argatroban/bivalirudin] on tests of haemostasis

CONGRESS 2023 - Transforming your pathology workforce

Join your network workforce leads/practice educators for a solution focused discussion around workforce challenges. Find out about current education and development opportunities with specific emphasis on support workers, advanced clinical practice and leadership. We welcome your participation in helping to shape the future of your pathology workforce.

You are invited by the speakers to complete this online form before the presentation

CONGRESS 2023 - Idiopathic Membranous Nephropathy: PLA2 and beyond

Idiopathic Membranous Nephropathy: PLA2 and beyond

CONGRESS 2023 - The role of a Regional Newborn Screening laboratory

Newborn screening (NBS) is an essential public health strategy aimed at identifying newborn babies that are affected by certain genetic, metabolic and infectious conditions. NBS enables the early detection and management of several congenital disorders, which if left untreated, may lead to mental retardation and/or death. Early diagnosis and instigation of treatment, along with appropriate long-term care help ensure normal growth and development of the affected individual.

The Sheffield Regional NBS Laboratory is one of the largest newborn screening laboratories in the UK testing around 65,000 newborn bloodspot samples per year and has been an integral part of routine newborn care for the region of South Yorkshire, Lincolnshire and East Midlands. Newborn screening in the United Kingdom now includes screening for 10 conditions including multiple metabolic, haemoglobinopathies and only recently severe combined immunodeficiency - all detectable though multiplex laboratory procedures.

This presentation will briefly review the implementation of newborn screening in the region, including a brief history and justification for newborn screening, laboratory detection and diagnosis of the screening condition, the referral pathway/notification to a regional consultant paediatrician for initiation of treatment of the condition/follow up testing and conclude with a case study.
  1. 2
  2. 3
  3. 4
  4. 5
  5. 6
  6. 7
  7. 8
  8. 9
  9. 10
  10. 11